Org 28611

Org 28611
Legal status
Legal status
CAS Number 639068-99-8 N
PubChem (CID) 10091392
ChemSpider 8266929 YesY
Chemical and physical data
Formula C23H33N3O2
Molar mass 383.526 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic,[1] and while it achieved this aim and has progressed as far as Phase II clinical trials in humans as both a sedative and an analgesic, results against the comparison drugs (midazolam and morphine respectively) were not particularly favourable in initial testing.[2][3]

See also


  1. Adam, J. M.; et al. (2010). "Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists". MedChemComm. Royal Society of Chemistry. 1: 54. doi:10.1039/c0md00022a.
  2. Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF, van Gerven JM (August 2009). "Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers". Journal of Psychopharmacology (Oxford, England). 23 (6): 633–44. doi:10.1177/0269881108091551. PMID 18635703.
  3. A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery

This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.